Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor ... Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors. Mostra di più
| Periodo † | Var | Var % | Apert. | Max | Min | Med. Vol. Giorn. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.234 | 27.0207852194 | 0.866 | 1.14 | 0.83 | 1685678 | 0.98131841 | CS |
| 4 | -0.2941 | -21.0960476293 | 1.3941 | 1.3941 | 0.783 | 1281854 | 1.06828517 | CS |
| 12 | -0.93 | -45.8128078818 | 2.03 | 2.3 | 0.783 | 1166403 | 1.51303096 | CS |
| 26 | -1.24 | -52.9914529915 | 2.34 | 3.39 | 0.783 | 1402331 | 2.0126569 | CS |
| 52 | -3.54 | -76.2931034483 | 4.64 | 5.66 | 0.783 | 1267471 | 2.42094178 | CS |
| 156 | -11.92 | -91.5514592934 | 13.02 | 47.2508 | 0.783 | 1328463 | 10.58291427 | CS |
| 260 | -17.55 | -94.1018766756 | 18.65 | 47.2508 | 0.783 | 1169037 | 10.71615499 | CS |
Le azioni che visualizzerai appariranno in questo riquadro, così potrai facilmente tornare alle quotazioni di tuo interesse.
Assistenza: support@advfn.it
Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni
Caratteristiche principali
Premium
